---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-033143"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2023-09-20T23:59:59+00:00"
generated_at: "2026-06-10T12:08:41.853042+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Oncocyte subleases 13,400 sq ft of Irvine office to Induce Biologics

## Summary
- Sublease covers initially 13,400 sq ft, expanding to full ~26,800 sq ft after 18 months.
- Monthly base rent starts at $36,850, escalating to $80,534 by 2027; term ends Oct 31, 2027.
- Subtenant pays a $101,987 security deposit and 50% of expenses/taxes during initial period.
- Sublease became effective Sept 14, 2023 after landlord consent; commencement 120 days later.

## SEC filing metadata
- accession: 0001493152-23-033143
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2023-09-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315223033143/0001493152-23-033143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315223033143/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-033143
- JSON: https://secwatch.observer/filing/0001493152-23-033143.json
- Plain text: https://secwatch.observer/filing/0001493152-23-033143.txt

## Key facts
- Material Agreements
  Insight Molecular Diagnostics Inc. entered into Sublease Agreement with Induce Biologics USA, Inc. valued at Monthly base rent starting at $36,850.00, security deposit of $101,987.38 (effective 2023-09-14).
  - Action: entry
  - Agreement: lease
  - Counterparty: Induce Biologics USA, Inc.
  - Value: Monthly base rent starting at $36,850.00, security deposit of $101,987.38
  - Effective: 2023-09-14
  source text: On August 8, 2023, Oncocyte Corporation (the “ Company ”) and Induce Biologics USA, Inc. (“ Subtenant ”) entered into a Sublease Agreement (the “ Sublease Agreement ”), which subsequently became effective as of September 14, 2023, upon the execution and delivery by the Company, Subtenant, and Cushing Ventures, LLC (“ Landlord ”), of that certain Landlord’s Consent to Sublease dated September 12, 2023 (the “ Consent Agreement ”), under which Landlord consented to the Sublease Agreement, on the terms and subject to the conditions set forth therein.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223033143/0001493152-23-033143-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.